Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.

Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortes-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, Olsen C, Kim J, Taylor AM, Cherniack AD, Akbani R, Suphavilai C, Nagarajan N, Stuart JM, Mills GB, Wyczalkowski MA, Vincent BG, Hutter CM, Zenklusen JC, Hoadley KA, Wendl MC, Shmulevich L, Lazar AJ, Wheeler DA, Getz G (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Book Volume: 173

Pages Range: 305-320.e10

Journal Issue: 2

DOI: 10.1016/j.cell.2018.03.033

Abstract

The Cancer Genome Atlas (TCGA) has catalyzed systematic characterization of diverse genomic alterations underlying human cancers. At this historic junction marking the completion of genomic characterization of over 11,000 tumors from 33 cancer types, we present our current understanding of the molecular processes governing oncogenesis. We illustrate our insights into cancer through synthesis of the findings of the TCGA PanCancer Atlas project on three facets of oncogenesis: (1) somatic driver mutations, germline pathogenic variants, and their interactions in the tumor; (2) the influence of the tumor genome and epigenome on transcriptome and proteome; and (3) the relationship between tumor and the microenvironment, including implications for drugs targeting driver events and immunotherapies. These results will anchor future characterization of rare and common tumor types, primary and relapsed tumors, and cancers across ancestry groups and will guide the deployment of clinical genomic sequencing.

Involved external institutions

Washington University United States (USA) (US) Barcelona Supercomputing Center / Centro Nacional de Supercomputación Spain (ES) Institute for Systems Biology United States (USA) (US) Université libre de Bruxelles (ULB) / Free University of Brussels Belgium (BE) Genome Institute of Singapore Singapore (SG) Johns Hopkins University (JHU) United States (USA) (US) Harvard University United States (USA) (US) H3 Biomedicine United States (USA) (US) Houston Texas Medical Center United States (USA) (US) Eli and Edythe L. Broad Institute of MIT and Harvard United States (USA) (US) University of Texas MD Anderson Cancer Center United States (USA) (US) University of California Santa Cruz United States (USA) (US) University of North Carolina at Chapel Hill United States (USA) (US) National Human Genome Research Institute (NHGRI) United States (USA) (US) National Cancer Institute (NCI) United States (USA) (US)

How to cite

APA:

Ding, L., Bailey, M.H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D.,... Getz, G. (2018). Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 173(2), 305-320.e10. https://doi.org/10.1016/j.cell.2018.03.033

MLA:

Ding, Li, et al. "Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics." Cell 173.2 (2018): 305-320.e10.

BibTeX: Download